Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carvedilol + prazosin is a combination of two antihypertensive agents, each with distinct but complementary mechanisms of action. Carvedilol is a non-selective beta-adrenergic antagonist with additional alpha-1 adrenergic blocking activity, used primarily for the treatment of hypertension, heart failure, and left ventricular dysfunction following myocardial infarction. Prazosin is an alpha-1 adrenergic receptor antagonist that lowers blood pressure by relaxing vascular smooth muscle and decreasing peripheral resistance. The combination may theoretically provide additive antihypertensive effects; however, concurrent use increases the risk of adverse effects such as hypotension due to dual alpha-1 blockade. This combination should be used cautiously and typically only under special circumstances with close monitoring[2][7][5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carvedilol + prazosin.